Annual Report 2024 released by Scantox Group

With the acquisitions made in 2024, Scantox is now able to deliver a full range of services - from early-stage lead identification and regulatory-requested safety studies through to on-market drug support. With the acquisitions made in 2024, Scantox is now able to deliver a full range of services - from early-stage lead identification and regulatory-requested safety studies through to on-market drug support. "We have in 2024 continued to demonstrate our commitment to expanding both service...

With the acquisitions made in 2024, Scantox is now able to deliver a full range of services - from early-stage lead identification and regulatory-requested safety studies through to on-market drug support.

"We have in 2024 continued to demonstrate our commitment to expanding both service offerings and geographic reach, serving as a "one-stop-shop" to foster deeper collaboration, whilst remaining steadfast to our core value: being a trusted partner that delivers high-quality, science-led interactions from first contact to final report," Christensen explains.

"Going forward, Scantox will continue to grow our business with both new and existing clients - from virtual biotech companies to the largest global pharma companies - by offering an ever-expanding portfolio of high-quality services. Simultaneously, we are investing in our operations to digitize processes and introduce new models where they benefit our clients."

Scantox is a leading preclinical contract research organization (CRO) accelerating the drug discovery and development process for clients worldwide with a service portfolio covering all main areas within Discovery, Regulatory Toxicology and Analytical Services. The company is headquartered in Denmark, with subsidiaries in Denmark, Sweden, Austria and the UK.

Read the full report:  https://scantox.com/about-scantox/annual-report/

Logo: https://mma.prnewswire.com/media/2674623/ScantoGroup_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/annual-report-2024-released-by-scantox-group-302439537.html